These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21992031)

  • 41. Auditing drug metabolism protocols, data, and reports.
    Lucas G; Walls S
    Qual Assur; 1994 Jun; 3(2):193-7. PubMed ID: 7804636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
    Roffey SJ; Obach RS; Gedge JI; Smith DA
    Drug Metab Rev; 2007; 39(1):17-43. PubMed ID: 17364879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O; Tolonen A; Korjamo T; Turpeinen M; Raunio H
    Bioanalysis; 2009 May; 1(2):393-414. PubMed ID: 21083174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of radioactive compounds and autoradiography to determine drug tissue distribution.
    Solon EG
    Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The role of ADME evaluation in translation research of innovative drug].
    Liu Y; Hong L; Yu LS; Jiang HD; Chen JZ; Meng Q; Chen SQ; Zeng S
    Yao Xue Xue Bao; 2011 Jan; 46(1):19-29. PubMed ID: 21465804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic profiling as a tool for understanding mechanisms of toxicity.
    Clarke CJ; Haselden JN
    Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and evaluation of a multiple-plate fraction collector for sample processing: application to radioprofiling in drug metabolism studies.
    Barros A; Ly VT; Chando TJ; Ruan Q; Donenfeld SL; Holub DP; Christopher LJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):979-86. PubMed ID: 21168298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-dimensional liquid chromatography/mass spectrometry set-up for structural elucidation of metabolites in complex biological matrices.
    Kiffe M; Graf D; Trunzer M
    Rapid Commun Mass Spectrom; 2007; 21(6):961-70. PubMed ID: 17299833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
    Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
    Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The state of the art: a commentary on the current practice of metabolism and pharmacokinetic studies in the pharmaceutical industry.
    Case DE
    Xenobiotica; 1981 Dec; 11(12):803-14. PubMed ID: 7342486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites.
    Ma S; Chowdhury SK
    Bioanalysis; 2012 Mar; 4(5):501-10. PubMed ID: 22409549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH
    Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.